These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 11533015)

  • 1. Intracellular penetration and bactericidal activity of the novel des-fluoro(6) quinolone, BMS-284756.
    Kolek B; Warr G; Bonner D; Fung-Tomc J
    J Antimicrob Chemother; 2001 Sep; 48(3):445-6. PubMed ID: 11533015
    [No Abstract]   [Full Text] [Related]  

  • 2. Increased in vitro activity of the novel des-fluoro(6) quinolone BMS-284756 against genetically defined clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Boos M; Mayer S; Jagusch H; Fluit AC
    J Antimicrob Chemother; 2002 Feb; 49(2):283-7. PubMed ID: 11815569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the novel des-fluoro(6) quinolone BMS-284756 against methicillin-susceptible and -resistant staphylococci.
    Fung-Tomc J; Valera L; Minassian B; Bonner D; Gradelski E
    J Antimicrob Chemother; 2001 Nov; 48(5):735-8. PubMed ID: 11679566
    [No Abstract]   [Full Text] [Related]  

  • 4. Antimicrobial activity of BMS 284756, a novel des-fluoro (6) quinolone and seven fluoroquinolones against Streptococcus pneumoniae.
    Saravolatz L; Manzor O; Pawlak J; Belian B
    Clin Microbiol Infect; 2001 Oct; 7(10):572-3. PubMed ID: 11683802
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro activities of novel des-fluoro(6) quinolone BMS-284756 against mutants of Streptococcus pneumoniae, Streptococcus pyogenes, and Staphylococcus aureus selected with different quinolones.
    Schmitz FJ; Boos M; Mayer S; Köhrer K; Scheuring S; Fluit AC
    Antimicrob Agents Chemother; 2002 Mar; 46(3):934-5. PubMed ID: 11850293
    [No Abstract]   [Full Text] [Related]  

  • 6. The in vitro activity of BMS-284756, a new des-fluorinated quinolone.
    Weller TM; Andrews JM; Jevons G; Wise R
    J Antimicrob Chemother; 2002 Jan; 49(1):177-84. PubMed ID: 11751785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of the novel des-F(6) quinolone BMS-284756 against genetically characterized clinical streptococcal isolates, including isolates with reduced quinolone susceptibility.
    Schmitz FJ; Milatovic D; Boos M; Mayer S; Fluit AC
    J Antimicrob Chemother; 2002 Apr; 49(4):698-701. PubMed ID: 11909849
    [No Abstract]   [Full Text] [Related]  

  • 8. Staphylococcus aureus mutants selected by BMS-284756.
    Discotto LF; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3273-5. PubMed ID: 11600399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of AUC/MIC ratios on the pharmacodynamics of the des-F(6) quinolone garenoxacin (BMS-284756) is similar to other fluoroquinolones.
    Lister PD
    J Antimicrob Chemother; 2003 Jan; 51(1):199-202. PubMed ID: 12493819
    [No Abstract]   [Full Text] [Related]  

  • 10. Mechanism of action of the des-F(6) quinolone BMS-284756 measured by supercoiling inhibition and cleavable complex assays.
    Wu P; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3660-2. PubMed ID: 11709365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activities of the des-fluoro(6) Quinolone BMS-284756 against aerobic and anaerobic pathogens isolated from skin and soft tissue animal and human bite wound infections.
    Goldstein EJ; Citron DM; Merriam CV; Warren YA; Tyrrell KL; Fernandez H
    Antimicrob Agents Chemother; 2002 Mar; 46(3):866-70. PubMed ID: 11850275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Killing kinetics of four quinolones against gram-positive cocci.
    Cantón E; Ramon MS; Jimenez MT; Martinez JP
    Chemotherapy; 1993; 39(6):394-9. PubMed ID: 8222866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antianaerobic activity of BMS 284756.
    Hoellman DB; Kelly LM; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 2001 Feb; 45(2):589-92. PubMed ID: 11158759
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756).
    Hayashi K; Takahata M; Kawamura Y; Todo Y
    Arzneimittelforschung; 2002; 52(12):903-13. PubMed ID: 12572531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS-284756), against rapidly growing mycobacteria and Nocardia isolates.
    Valera L; Gradelski E; Huczko E; Washo T; Yigit H; Fung-Tomc J
    J Antimicrob Chemother; 2002 Jul; 50(1):140-2. PubMed ID: 12096023
    [No Abstract]   [Full Text] [Related]  

  • 16. The inhibition and selectivity of bacterial topoisomerases by BMS-284756 and its analogues.
    Lawrence LE; Wu P; Fan L; Gouveia KE; Card A; Casperson M; Denbleyker K; Barrett JF
    J Antimicrob Chemother; 2001 Aug; 48(2):195-201. PubMed ID: 11481288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMS-284756 in experimental cephalosporin-resistant pneumococcal meningitis.
    Rodriguez-Cerrato V; Ghaffar F; Saavedra J; Michelow IC; Hardy RD; Iglehart J; Olsen K; McCracken GH
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3098-103. PubMed ID: 11600362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ecological impact of the des-F(6)-quinolone, BMS-284756, on the normal intestinal microflora.
    Nord CE; Gajjar DA; Grasela DM
    Clin Microbiol Infect; 2002 Apr; 8(4):229-39. PubMed ID: 12047415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection and genetic characterization of Streptococcus pneumoniae mutants resistant to the des-F(6) quinolone BMS-284756.
    Hartman-Neumann S; DenBleyker K; Pelosi LA; Lawrence LE; Barrett JF; Dougherty TJ
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2865-70. PubMed ID: 11557482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY antimicrobial surveillance program medical centers in Latin America (1999).
    Gales A; Sader H; Jones RN;
    Antimicrob Agents Chemother; 2001 May; 45(5):1463-6. PubMed ID: 11302811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.